New group program aims to help schizophrenia patients spot relapse early

NCT ID NCT07327944

Not yet recruiting Disease control Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a group psychoeducation program for people with schizophrenia to help them manage relapse and improve functional recovery. Sixty participants will be split into two groups: one receives the program (four 60-minute sessions) and the other does not. Researchers will measure changes in the ability to recognize early warning signs of relapse and overall functioning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Relapse Management Group Psychoeducation Program
What this could lead to: If successful, this program could provide a practical, low-cost tool to help people with schizophrenia recognize early warning signs of relapse and improve their daily functioning.
What could go wrong: This is a small, early-stage study with only 60 participants, so results may not apply widely. The program is short (four sessions) and may not produce lasting benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSE MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSE MANAGEMENT

More trials for these conditions

Other studies related to the condition(s) this trial covers.